Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Biotech saw positive results this quarter; shares still tanked. Here are some explanations

  • Adam Feuerstein

By Adam Feuerstein March 28, 2018

Reprints

Our Biotech Q1 Scorecard is filled up. Events happened, and ended mostly positive. Stocks moved, mostly down.

Which is … not what you might expect.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Call it data liberation day: Patients can now access…
Call it data liberation day: Patients can now access all their health records digitally  
23andMe had devastating news about my health. I wish…
23andMe had devastating news about my health. I wish a person had delivered it
When women are denied an abortion, their children fare…
When women are denied an abortion, their children fare worse than peers
New research may give geneticists a long-sought tool: a…
New research may give geneticists a long-sought tool: a targeted protein delivery device
British Columbia to bar Americans from buying Ozempic over…
British Columbia to bar Americans from buying Ozempic over supply concerns
Pharmalittle: WHO may add obesity drugs to essential medicines…
Pharmalittle: WHO may add obesity drugs to essential medicines list; monkey shortage may delay drug development

Recommended Stories